$Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors$

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

This multicenter phase I study aimed to establish the recommended dose (RD) of the epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with radiotherapy to children with malignant brain tumors. Group 1 included patients with refractory or relapsing brain tumors recei...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2011-01, Vol.13 (1), p.109-118
Hauptverfasser:	Geoerger, Birgit, Hargrave, Darren, Thomas, Fabienne, Ndiaye, Anna, Frappaz, Didier, Andreiuolo, Felipe, Varlet, Pascale, Aerts, Isabelle, Riccardi, Riccardo, Jaspan, Timothy, Chatelut, Etienne, Le Deley, Marie-Cecile, Paoletti, Xavier, Saint-Rose, Christian, Leblond, Pierre, Morland, Bruce, Gentet, Jean-Claude, Méresse, Valérie, Vassal, Gilles
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Brain Stem Neoplasms - drug therapy Child Child, Preschool Clinical Investigations Erlotinib Hydrochloride Female Glioma - drug therapy Humans Infant Male Maximum Tolerated Dose Neoplasm Recurrence, Local - drug therapy Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Quinazolines - pharmacokinetics Quinazolines - therapeutic use Survival Rate Therapies, Investigational Tissue Distribution Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!